BRAF and melanoma: Besides the biological differences between NRAS and BRAF mutated melanoma, the poor outcome might also be related to a weaker response of NRAS mutated melanoma compared to BRAF mutated melanomas to current targeted therapy (i.e. vemurafenib, dabrafenib with or without MAPK inhibitors)7.